Data / Drug companies / Prostacycline Vasodilator
Prostacycline Vasodilator drugs: 2 drugs from 10 companies in the FDA NDC directory
Prostacycline Vasodilator is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 49 products in this class from 10 companies, covering 2 drugs by generic name. The main marketing category is new drug applications (NDA), and the newest product started marketing on December 29, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 10Companies
- 49Products
- 2Drugs by generic name
Drugs in the Prostacycline Vasodilator class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Treprostinil | 41 | 6 |
| Epoprostenol | 8 | 4 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| United Therapeutics Corporation | 21 | inhalant; injection, solution | New drug applications (NDA) | October 24, 2024 |
| Alembic Pharmaceuticals Inc. | 4 | injection, solution | Generic drugs (ANDA) | February 11, 2021 |
| Dr. Reddy's Laboratories Inc. | 4 | injection, solution | Generic drugs (ANDA) | February 13, 2023 |
| Liquidia Technologies, Inc. | 4 | capsule | New drug applications (NDA) | May 23, 2025 |
| Sandoz Inc | 4 | injection | Generic drugs (ANDA) | March 25, 2019 |
| Teva Parenteral Medicines, Inc. | 4 | injection, solution | Generic drugs (ANDA) | September 30, 2019 |
| Actelion Pharmaceuticals US, Inc. | 2 | injection, powder, lyophilized, for solution | New drug applications (NDA) | April 22, 2010 |
| Gland Pharma Limited | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 29, 2025 |
| Mylan Institutional LLC | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 25, 2024 |
| Sun Pharmaceutical Industries, Inc. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 16, 2021 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 17 | 34.7% |
| Inhalant | 11 | 22.4% |
| Injection, powder, lyophilized, for solution | 8 | 16.3% |
| Tablet, extended release | 5 | 10.2% |
| Capsule | 4 | 8.2% |
| Injection | 4 | 8.2% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.